ImmunID Gains Worldwide Assays Patents

ImmunID has secured patents in the U.S., EU, Canada and Japan covering the underlying technology of its ImmunTraCkeR and ImmunIG assays.

The assays work by evaluating the immune system’s stock of T- and B-cells, and are meant to predict and monitor the body’s response to immune-oncology therapies, the French devicemaker said Wednesday.

The ImmunTraCkeR, which is referred to as the company’s flagship product on its website, is CE Mark-certified. Clinical trials evaluating both assays are underway. — Jason Scott